Multidrug-Resistant Genotypes of Plasmodium falciparum, Myanmar

Zhaoqing Yang,1 Chaojun Li,1 Miao Miao, Zaixing Zhang, Xiaodong Sun, Hao Meng, Jie Li, Qi Fan, and Liwang Cui

We performed a molecular epidemiologic survey of mutations associated with drug-resistance genes in Plasmodium falciparum in northeastern Myanmar. In this region, 3 highly mutated drug-resistance haplotypes and 1 associated with decreased quinine susceptibility were prevalent, which suggests that parasites may be resistant to multiple commonly used antimalarial drugs.

Multidrug-resistant malaria is a major impediment to socioeconomic development in the Greater Mekong Subregion (GMS) of Southeast Asia (1). Malaria distribution in the GMS is extremely uneven, with areas of high endemicity in some countries and along international borders. In Myanmar, malaria is particularly problematic; more than half of malaria cases and approximately three fourths of malaria-related deaths in the GMS during 2007–2009 occurred in Myanmar. The GMS has been the breeding ground of half of malaria cases and approximately three fourths of malaria cases, respectively. Finger-prick blood samples were obtained from 260 patients with uncomplicated P. falciparum infection who had not used antimalarial drugs during the previous 2 weeks. Parasite DNA was extracted from filter papers and genotyped at 3 polymorphic genes, which detected 54.6% of samples containing mixed-strain infections (5). Of the 118 samples with monoclonal infection, 117 samples were successfully genotyped by PCR and sequencing at 5 known and putative drug-resistance genes (online Technical Appendix Table, www.cdc.gov/eid/content/17/3/498-Techapp.pdf), some of which have been widely used for resistance surveillance and as predictors of clinical efficacy of antimalarial drugs.

The Study

We screened by microscopy 4,980 patients with febrile illness who sought care at a malaria clinic in Kachin State, northeastern Myanmar, during 2007–2009; a total of 27.9% had malaria infections. P. falciparum, P. vivax, and mixed species infections accounted for 56.7%, 41.1%, and 2.2% of malaria cases, respectively. Finger-prick blood samples were obtained from 260 patients with uncomplicated P. falciparum infection who had not used antimalarial drugs during the previous 2 weeks. Parasite DNA was extracted from filter papers and genotyped at 3 polymorphic genes, which detected 54.6% of samples containing mixed-strain infections (5). Of the 118 samples with monoclonal infection, 117 samples were successfully genotyped by PCR and sequencing at 5 known and putative drug-resistance genes (online Technical Appendix Table, www.cdc.gov/eid/content/17/3/498-Techapp.pdf), some of which have been widely used for resistance surveillance and as predictors of clinical efficacy of antimalarial drugs.

We performed a molecular epidemiologic survey of mutations associated with drug-resistance genes in Plasmodium falciparum in northeastern Myanmar. In this region, 3 highly mutated drug-resistance haplotypes and 1 associated with decreased quinine susceptibility were prevalent, which suggests that parasites may be resistant to multiple commonly used antimalarial drugs.
Multidrug-Resistant P. falciparum, Myanmar

contained at least double mutations 59R/108N. Two triple-mutation haplotypes (NRNL and IRNI, mutations in *boldface*) were detected with NRNL being more frequent than IRNI in each year. Overall, quadruple mutations (IRNL) were found in >50% of the samples. In addition, frequency of triple and quadruple mutations increased gradually from 2007 to 2009. We found all 5 haplotypes in 2007 but only triple and quadruple mutations in 2009.

In *pfhps*, 10 haplotypes were found, and 437G and 540E/N mutations were highly prevalent: 98.3 and 96.6%, respectively (Table 1). Similarly, the wild-type *pfhps* haplotype SGKA was found in only 2 samples. AGEA was the most common haplotype in each year and reached an overall frequency of 48.7%. Quadruple mutations (AGEG) were found only in 2008 and 2009.

Molecular analysis of drug-resistance markers in monoclonal infections enabled us to obtain multilocus genotypes of the parasites. Genotyping each of the 117 parasite isolates at 16 drug resistance–related codons in the *pfcr*, *pfmdr1*, *pfhfr*, and *pfhps* genes showed 41 haplotypes (Figure 1). Among these haplotypes, parasites containing ≥10 mutated codons accounted for 93.2% of the samples.

Polymorphisms in the minisatellite ms4760 of *P. falciparum* Na+/H+ exchanger (*pfne1*) are associated with quinine sensitivity (5,7–10). Sequencing of the *pfne1* fragment containing the ms4760 minisatellite from 79 monoclonal infections showed 10 haplotypes, with haplotype 7 the most predominant (54.4%) (Table 2). More than 64% of samples tested contained ≥3 copies of the DNNND repeat (Rep1); 76% contained 1 copy of the NHDNHNNDND repeat (Rep2). Accordingly, >60% of parasite isolates had a Rep1:Rep2 ratio of ≥3:1.

Conclusions

In Myanmar, high-level resistance to chloroquine and pyrimethamine–sulfadoxine was reported more than a decade ago (11–13). Our molecular survey showed that the major chloroquine resistance allele CVIET has reached fixation, and triple and quadruple mutations in *pfhfr* and *pfhps* were highly prevalent in this region. These findings strongly suggest that a large proportion of parasites might show clinical resistance to chloroquine and antifolate drugs. Although chloroquine has been withdrawn from treating *P. falciparum* malaria for decades in some regions,
In vitro and in vivo studies are required to corroborate these findings.

Acknowledgment

We thank Guofa Zhou for assistance with statistical analysis.

**Table 1. Prevalence of point mutation haplotypes in pfmdr1 and pfcr in clinical samples from Kachin State, northeast Myanmar, 2007–2009**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Haplotype</th>
<th>Codon†</th>
<th>2007, n = 41</th>
<th>2008, n = 40</th>
<th>2009, n = 36</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfmdr (51, 59, 108, 164)</td>
<td>Wild-type</td>
<td>NRNI</td>
<td>2.4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Double mutations</td>
<td>NRNL</td>
<td>31.7*</td>
<td>25.0*</td>
<td>36.1*</td>
</tr>
<tr>
<td></td>
<td>Quadruple mutations</td>
<td>IRNL</td>
<td>14.6*</td>
<td>7.9*</td>
<td>16.7*</td>
</tr>
<tr>
<td>Pfcr (436, 437, 540, 581)</td>
<td>Wild-type</td>
<td>SAKA</td>
<td>2.4</td>
<td>–</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>Single mutation</td>
<td>SGKA</td>
<td>2.5</td>
<td>–</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>Double mutations</td>
<td>SGEA</td>
<td>9.8</td>
<td>2.5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Quadruple mutations</td>
<td>SGNA</td>
<td>2.4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Triple mutations</td>
<td>SGEG</td>
<td>26.8*</td>
<td>35.0*</td>
<td>19.4c</td>
</tr>
<tr>
<td></td>
<td>Quadruple mutations</td>
<td>SGNG</td>
<td>2.4</td>
<td>2.5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Quadruple mutations</td>
<td>AGNA</td>
<td>7.3</td>
<td>–</td>
<td>8.3</td>
</tr>
<tr>
<td></td>
<td>Quadruple mutations</td>
<td>AGEG</td>
<td>–</td>
<td>10.0</td>
<td>11.1</td>
</tr>
<tr>
<td></td>
<td>Quadruple mutations</td>
<td>AGNG</td>
<td>–</td>
<td>2.5</td>
<td>2.8</td>
</tr>
</tbody>
</table>

*Pfmdr, Plasmodium falciparum multi-resistant transporter; Pfcr, P. falciparum chloroquine resistance transporter; –, no such haplotype detected.
†Codons in **boldface** indicate mutated amino acids.
‡χ² test was performed with all data points of the 2 genes, which showed that overall haplotype prevalence differed significantly between the years (χ² test, p<0.0001, χ² = 76.49, df = 28). Major *dhfr* and *dhps* haplotypes were individually compared. For each haplotype (in the same row), the labeling by different letters denotes significant difference between the years (χ² test, p<0.05).

The *pfcr* resistance alleles showed no sign of abating (6). Furthermore, despite adoption of artemisinin combination therapy in 2002, the frequency of highly mutated *pfmdr1* and *pfcr* haplotypes appeared to have increased during this study, which suggested that artemisinin combination therapy might not have retarded the spread of antifolate-resistant parasites. This situation differs from that in the western Myanmar border area but is similar to that in Thailand and Cambodia, where highly mutated *pfmdr1* and *pfcr* genotypes also were common (14,15).

Mutations in *pfmdr1* are associated with resistance to several antimalarial drugs including chloroquine, mefloquine, and quinine and increased *pfmdr1* copy number is responsible for mefloquine resistance. We found that ≈60% of the parasites contained the wild-type *pfmdr1* allele, similar to some parasites from the western Myanmar border area (15). No *pfmdr1* amplification was detected, suggesting that parasites from this region might be mefloquine sensitive, consistent with the fact that mefloquine has not been deployed here. In contrast, in vitro mefloquine resistance was observed in southeast Myanmar bordering Thailand (13), possibly because of the extensive use of mefloquine in Thailand for the past 2 decades.

Although the validity of *pfne1* minisatellite polymorphism for predicting quinine resistance remains uncertain and may depend on the parasites’ origins (7–9), we detected significant association of decreased quinine susceptibility with increased DNNND repeat copies (5). We have provided further evidence on the high prevalence of parasites with increased DNNND repeats in *pfne1*, which suggests that some parasite strains might show reduced sensitivity to quinine.

Overall, our molecular survey of antimalarial drug resistance in *P. falciparum* showed high frequency of multidrug-resistant haplotypes in northeastern Myanmar. Moreover, parasites in this region had unique multilocus genotypes that differed markedly from those in other areas of the GMS. These findings suggest that coordinated efforts are necessary to thwart the spread of resistant strains across larger geographic regions. Our molecular study showed only the genotypes of the drug resistance genes; further in vitro and in vivo studies are required to corroborate these findings.
This study was supported by 1R01AI075429 and 1U19AI089672 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and by grant no. 30960050 from the National Science Foundation of China.

Dr Yang is a professor at the Department of Parasitology, Kunming Medical University, Yunnan, People’s Republic of China. Her primary research interests are epidemiology of drug resistance in malaria parasites.

References


Address for correspondence: Liwang Cui, Department of Entomology, The Pennsylvania State University, 501 ASI Bldg, University Park, PA 16801, USA; email: luc2@psu.edu

Like our podcasts?
Sign up to receive email announcements when a new podcast is available.

www.cdc.gov/ncidod/eid/subscribe.htm